Author:
Guyot Anne-Cécile,Leuxe Charlotte,Disdier Clémence,Oumata Nassima,Costa Narciso,Roux Gwenaëlle Le,Varela Paloma F.,Duchon Arnaud,Charbonnier Jean Baptiste,Herault Yann,Pavoni Serena,Galons Hervé,Andriambeloson Emile,Wagner Stéphanie,Meijer Laurent,Lund Amie K.,Mabondzo Aloïse
Abstract
AbstractNeurodegenerative diseases, including Alzheimer’s and Parkinson’s disease, are characterized by increased protein aggregation in the brain, progressive neuronal loss, increased inflammation, and neurogenesis impairment. We analyzed the effects of a new purine derivative drug, PDD005, in attenuating mechanisms involved in the pathogenesis of neurodegenerative diseases, using both in vivo and in vitro models. We show that PDD005 is distributed to the brain and can rescue cognitive deficits associated with aging in mice. Treatment with PDD005 prevents impairment of neurogenesis by increasing sex-determining region Y-box 2, nestin, and also enhances synaptic function through upregulation of synaptophysin and postsynaptic density protein 95. PDD005 treatment also reduced neuro-inflammation by decreasing interleukin-1β expression, activation of astrocytes, and microglia. We identified prohibitin as a potential target in mediating the therapeutic effects of PDD005 for the treatment of cognitive deficit in aging mice. Additionally, in the current study, glycogen synthase kinase appears to attenuate tau pathology.
Publisher
Springer Science and Business Media LLC
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献